Biofourmis Buys Biovotion to Deliver Precise Interventions for Patients with Complex Chronic Conditions

Biofourmis buys Biovotion
Biovotion’s Everion wearable device can measure 22 parameters in real time (Image credit: Biovotion)
US-based digital therapeutics company Biofourmis has signed an agreement to buy Zurich, Switzerland-based wearable biosensor company Biovotion. The deal consists of all Biovotion’s assets, including the clinical-grade Everion® device and over 60 global patents. Read more Fighting Against NCDs – Wearables for Chronic Disease Management and Mobility Challenges The acquisition of Biovotion enables Biofourmis to […]